Skip to main content
Fig. 3 | Molecular Neurodegeneration

Fig. 3

From: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

Fig. 3

Alzheimer’s disease Specific Markers Graphs showing the results of the multiplexed MRM-based LC-MS/MS assay of protein biomarkers quantitated in the CSF of control. Lewy body dementia (LBD). Parkinson’s disease (PD) and Alzheimer’s disease (AD). All 4 markers show changes in AD specific from other neurodegenerative disease groups and controls. No significant changes are observed in the PD group * Denotes new marker not described previously

Back to article page